|
Published by: SMI Publishing, Ltd
Published: Jun. 4, 2007
Table of Contents
- Day One
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Boris Simkovich, President, Light Management Consulting LLC.
- 9.10 KEYNOTE OPENING ADDRESS
- The changing landscape of North American pricing and reimbursement
- The current pricing and reimbursement structure in North America
- Potential changes in the U.S. P&R system
- - Who are the key stakeholders and influencers?
- - How will the change in party leadership affect the P&R system?
- The impact of European P&R reforms on the North American market
- Boris Simkovich, President, Light Management Consulting LLC.
- 9.50 WORKING WITH LOCAL REGULATORS WHILST MAINTAINING AN INTERNATIONAL STRATEGY
- Anne-Toni Rodgers, Director, Government Affairs & Public Policy Europe, Baxter World Trade S. A.
- 10.30 Morning Coffee
- 11.00 STATE MEDICAID
- Effects of Medicare Part D in the market
- The move from Medicaid to Medicare - and how that may and will affect reimbursement and pricing?
- How have changes affected the pharmaceutical industry?
- The impact of Medicare Part D had on state insurance programs, including Medicaid, state drug assistance plans, and other programs?
- Donald Zowader, Manager, Government Affairs, Takeda Pharmaceuticals.
- 12.20 Networking Lunch
- 1.50 FUTURE PRICING SCENARIOS IN THE USA
- What could happen in the pricing and reimbursement arena now that there has been a party leadership change in Congress in the US?
- What types of moves will the Democrats make that the Republicans have not made?
- Will there continue to be a non-interference policy in the Medicare Part-D legislation that precludes direct governmental negotation with drug manufacturers?
- The effect of the public relese of Average Manufacturers Price AMP data and other Deficit Reduction Act provision of 2005 as well as transparency legislation on
- Deborah Williams, Director, Government Affairs and Public Policy, Baxter Healthcare Corporation.
- 3.10 Afternoon Tea
- 3.40 PRICING IMPLICATIONS FOR PHYSICIAN-ADMINISTERED PRODUCTS
- A discussion focusing on the changing environment for physician use and pricing of oncology and other physician administered Drugs
- Ted Sweeney, Partner, PriceSpective .
- 5.00 Chairman’s Closing Remarks and Close of Day One
- Day two
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Boris Simkovich, President, Light Management Consulting LLC.
- 9.10 EUROPE, NORTH AMERICA AND BEYOND
- A comparison of pricing methodologies in a competitive marketplace
- What are the main differences between US and European pricing and reimbursement structures?
- What can we learn from other markets - for example, Japan?
- How does the pricing of drugs within the European market affect the price in North America?
- How the P&R environment change in light of an expanding Europe
- Gary Johnson, Managing Director, Inpharmation.
- 9.50 MEDICARE PART D: A MOVE TOWARDS COST CONTROL FOR DRUGS?
- What approaches have been taken in EU (e.g. reference prices)
- Difference between EU system and US system
- Strategies for pharma moving forwards
- Curtis Moore, Manager, Global Sales & Price Operations, Genzyme Corporation.
- 10.30 Morning Coffee
- 11.00 THE CANADIAN PERSPECTIVE
- Overview of Canadian pricing and reimbursement and the impact of
- What are the main differences between the US and Canada?
- Canadian price regulation and the Patented Medicine Prices Review Board (PMPRB)
- Canadian reimbursement schemes and the impact of the Common Drug Review (CDR)
- Optimizing market access in Canada while respecting global pricing bands
- Canadian price increases: An endangered species?
- Impact of US Medicare Part D on Canada - impact of Canadian prices on the U.S.
- Prospects for Canada/US cross-border trade & re-importation
- The price gap between Canada, Europe and the United States - what are the implications?
- Canadian outlook: integration of government pricing & reimbursement schemes?
- Neil Palmer, Vice President, Pricing & Reimbursement, RTI Health Solutions.
- 11.40 OPTIMISING MARKET ACCESS IN NORTH AMERICA
- How can this be achieved successfully?
- How have benefit designs evolved, and what are the implications for pharmaceutical manufacturers?
- What are the main barriers hindering access to the North American market?
- What are typical formulary management tools and philosophies and how are they impacting access?
- What strategies have proved to be successful in the evolving marketplace?
- Pamela Santoni, Senior Principal, IMS Health.
- 12.20 Networking Lunch
- 1.50 GOVERNMENTAL BUYING POWER
- Medicare updates and the implications of the change in US congress leadership for the pharma industry
- Scott Roberts, Director, PriceSpective .
- 2.30 THE IMPORTANCE OF “GOOD SCIENCE” TO REIMBURSEMENT
- The use and credibility of outcomes data in a post-market research environment
- Quality and revenue are no longer separate issues the industry
- What can we expect in this arena?
- Is the US becoming more like the rest of the world in requiring that the "value" of new and existing drug products be demonstrated?
- Developing an agile communications strategy that highlights a product’s benefits
- Kathleen Hughes, Vice President & Director of Consulting Operations, Covance.
- Meridith Johnson, Senior Associate, Covance .
- 3.10 Afternoon Tea and Close of Conference
AbstractThe SMi Group's 3rd Annual Pricing and Reimbursement in North America Conference comes at an exciting and crucial time. With the introduction of Medicare Part D in 2006 combined with a party leadership change in Congress, North American Pricing and Reimbursement is currently undergoing one of its most dramatic periods in its history.
Senior figures from the pharmaceutical industry will explore the initial results of Medicare Part D from a pharma, payer and patient perspective, as well as contextualising North America within the Global Pricing and Reimbursement scene. Also included are keynote presentations on the importance of Parallel Trade and reimbursement of high-priced medication making the SMi Group's North American Pricing and Reimbursement Conference a necessary and unmissable event.
Don't miss the opportunity to listen to an excellent speaker panel, including:
- Anne-Toni Rodgers, Director, Government Affairs and Public Policy, Europe, Baxter World Trade
- Neil Palmer, Vice President, Pricing & Reimbursement, RTI Health Solutions
- Curtis Moore, Manager, Global Sales & Price Operations, Genzyme
- Kathy Hughes, Vice President & Director, Consulting Operations, Covance Market Access Services
- Ted Sweeney, Partner, PriceSpective
- Donald Zowader, Manager, Government Affairs, Takeda
- Dr Boris Simkovich, President, Light Management Consultancy LLC
- Gary Johnson, Managing Director, Inpharmation
This is an excellent forum for you to meet with an international selection of the industry’s key players to hear expert perspectives discussing:
- THE AFTER EFFECTS and impact upon the industry of the changing landscape in North American pricing and reimbursement
- EFFECTIVE approaches to working with regional pricing agencies whilst maintaining a global strategy
- WHAT is happening in regard to coverage, reimbursement, and general management of very high priced medication?
- A COMPARATIVE analysis of the expanding EU, USA and other foreign markets
- FUTURE pricing scenarios in North America
- HOW the North American market affects the global pharma industry
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
